Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 76 55 44 15 73
Fear of Open Spaces 12

Classifications:



External Ids:

Disease Ontology 12 DOID:593
ICD10 33 F40.0 F40.00
MeSH 44 D000379
NCIt 50 C34362
UMLS 73 C0001818

Summaries for Agoraphobia

Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to depression and social phobia. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Sertraline and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include colon, brain and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 76 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 depression 31.0 HTR1A MAOA SLC6A4
2 social phobia 30.9 HTR1A MAOA SLC6A4
3 personality disorder 30.8 HTR1A MAOA SLC6A4
4 obsessive-compulsive disorder 30.6 HTR1A MAOA SLC6A4
5 major depressive disorder 29.0 HTR1A MAOA SLC6A2 SLC6A4
6 generalized anxiety disorder 28.9 HTR1A MAOA RGS2 SLC6A2 SLC6A4
7 anxiety 28.8 CCKBR HTR1A MAOA PTK7 SLC6A2 SLC6A4
8 panic disorder 28.5 CCKBR HTR1A MAOA PTK7 RGS2 SLC6A2
9 alcohol dependence 28.5 HTR1A MAOA OPRK1 SLC6A4
10 panic disorder 1 11.2
11 psychosexual disorder 10.7 HTR1A SLC6A4
12 premature ejaculation 10.7 HTR1A SLC6A4
13 periodic limb movement disorder 10.6 HTR1A SLC6A4
14 alexithymia 10.6 HTR1A SLC6A4
15 intermittent explosive disorder 10.6 HTR1A SLC6A4
16 atypical depressive disorder 10.6 MAOA SLC6A4
17 pathological gambling 10.5 MAOA SLC6A4
18 migraine without aura 10.5 HTR1A SLC6A4
19 antisocial personality disorder 10.5 MAOA SLC6A4
20 paranoid schizophrenia 10.5 MAOA SLC6A4
21 early-onset schizophrenia 10.5 MAOA SLC6A4
22 bipolar i disorder 10.4 HTR1A SLC6A4
23 endogenous depression 10.4 MAOA SLC6A4
24 dyspepsia 10.4 HTR1A SLC6A4
25 kleptomania 10.3 HTR1A MAOA SLC6A4
26 obsessive-compulsive personality disorder 10.3 PIR SLC6A4
27 brunner syndrome 10.3 HTR1A MAOA SLC6A4
28 schizoid personality disorder 10.3 HTR1A PIR
29 postpartum depression 10.3 HTR1A MAOA SLC6A4
30 borderline personality disorder 10.3 HTR1A MAOA SLC6A4
31 serotonin syndrome 10.3 HTR1A MAOA SLC6A4
32 chronic fatigue syndrome 10.3 HTR1A MAOA SLC6A4
33 migraine with or without aura 1 10.2 HTR1A MAOA SLC6A4
34 cocaine abuse 10.2 SLC6A2 SLC6A4
35 sudden infant death syndrome 10.2 HTR1A MAOA SLC6A4
36 conduct disorder 10.2 MAOA SLC6A4
37 oppositional defiant disorder 10.0 MAOA SLC6A2 SLC6A4
38 bulimia nervosa 10.0 MAOA SLC6A4
39 eating disorder 10.0
40 dysthymic disorder 9.9 MAOA PIR SLC6A4
41 aging 9.9
42 separation anxiety disorder 9.9
43 thyroiditis 9.9
44 opiate dependence 9.9 OPRK1 SLC6A4
45 autism 9.8 GRPR HTR1A MAOA SLC6A4
46 hypochondriasis 9.8
47 melancholia 9.8
48 irritable bowel syndrome 9.8
49 substance abuse 9.8 MAOA SLC6A4
50 opioid addiction 9.8 CCKBR OPRK1

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia

Symptoms & Phenotypes for Agoraphobia

MGI Mouse Phenotypes related to Agoraphobia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 SLC6A4 CCKBR GRPR HTR1A MAOA OPRK1
2 cardiovascular system MP:0005385 9.76 SLC6A4 CCKBR STMN1 HTR1A MAOA PTK7
3 homeostasis/metabolism MP:0005376 9.56 SLC6A4 CCKBR STMN1 GRPR HTR1A MAOA
4 nervous system MP:0003631 9.28 SLC6A4 CCKBR STMN1 HTR1A MAOA OPRK1

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sertraline Approved Phase 4 79617-96-2 68617
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 1 28981-97-7 2118
4
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
5
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
6 Central Nervous System Depressants Phase 4,Phase 1
7 Central Nervous System Stimulants Phase 4
8 GABA Agents Phase 4,Phase 1
9 GABA Modulators Phase 4,Phase 1
10 Serotonin Agents Phase 4,Phase 3
11 Serotonin Uptake Inhibitors Phase 4,Phase 3
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Not Applicable
13 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
14 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
15 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
16 Tranquilizing Agents Phase 4,Phase 1
17 Anti-Anxiety Agents Phase 4,Phase 1,Not Applicable
18 Dopamine Agents Phase 4
19 Dopamine Uptake Inhibitors Phase 4
20 Hypnotics and Sedatives Phase 4,Phase 1
21 Anticonvulsants Phase 4
22 Antidepressive Agents Phase 4,Phase 3,Not Applicable
23 Antidepressive Agents, Second-Generation Phase 4,Phase 3
24 Lisdexamfetamine Dimesylate Phase 4
25 Psychotropic Drugs Phase 4,Phase 3,Phase 1
26 Rho(D) Immune Globulin Phase 4
27 gamma-Globulins Phase 4
28 Antibodies Phase 4
29 Immunoglobulins Phase 4
30 Immunoglobulins, Intravenous Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
32
Cycloserine Approved Phase 2 68-41-7 401 6234
33 Renal Agents Phase 2
34 Anti-Bacterial Agents Phase 2
35 Antibiotics, Antitubercular Phase 2
36 Anti-Infective Agents Phase 2
37 Antitubercular Agents Phase 2
38 Antimetabolites Phase 2
39
Citalopram Approved 59729-33-8 2771
40
Adenosine Approved, Investigational 58-61-7 60961
41
Propranolol Approved, Investigational Not Applicable 525-66-6 4946
42
Magnesium Sulfate Approved, Investigational, Vet_approved Not Applicable 7487-88-9 24083
43
Caffeine Approved, Nutraceutical 58-08-2 2519
44 Pharmaceutical Solutions Not Applicable
45 Analgesics
46 Cholinergic Agents
47 Muscarinic Antagonists
48 Cholinergic Antagonists
49 Parasympatholytics
50 Anti-Arrhythmia Agents ,Not Applicable

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
2 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
3 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
4 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
5 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
6 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
7 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
8 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
9 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
10 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Phase 2, Phase 3
11 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
12 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
13 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
14 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
15 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
16 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
17 Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia Completed NCT01928823 Phase 2 D-Cycloserine
18 Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia Completed NCT00576719 Phase 2
19 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
20 Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial Completed NCT01076777 Phase 2
21 Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder Completed NCT00705380 Phase 2
22 Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia Recruiting NCT01680237 Phase 2
23 Improve: Integrating Emotion Focused Components Into Psychological Therapy Recruiting NCT02822443 Phase 2
24 The Modular Protocol for Mental Health (MPMH) Enrolling by invitation NCT03143634 Phase 1, Phase 2
25 An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites Completed NCT01330472 Phase 1 Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
26 Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610 Not Applicable
27 Virtual Reality and Concept of Control in the Treatment of Acrophobia Unknown status NCT02020824 Not Applicable
28 Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway Unknown status NCT02150265 Not Applicable
29 Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma Unknown status NCT02030522 Not Applicable
30 Thought Field Therapy and Cognitive Therapy for Agoraphobia Completed NCT00932919 Not Applicable
31 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia Completed NCT01928810 Not Applicable
32 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia Completed NCT01446172
33 Mechanisms of Treatment Change in Panic Disorder and Agoraphobia Completed NCT03547180 Not Applicable
34 Cognitive Behavioral Therapy in Panic Disorder Completed NCT00772746
35 Internet-based Exposure Therapy for Panic Disorder Completed NCT03061448 Not Applicable
36 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder Completed NCT01788800 Not Applicable
37 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367 Not Applicable
38 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder? Completed NCT00202709 Not Applicable
39 Cognitive Behavior Psychotherapy in Panic Disorder Completed NCT01025908 Not Applicable
40 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366 Not Applicable
41 Interpretation Modification Program for Social Phobia Completed NCT00684541 Not Applicable
42 Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months Completed NCT00711737
43 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
44 Genetic Causes of Panic Disorder Completed NCT00083265
45 Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU) Completed NCT01207674 Not Applicable
46 A Randomized Controlled Trial of PCIT-ED for Preschool Depression Completed NCT02076425 Not Applicable
47 RCT of Bibliotherapy for Social Anxiety Disorder as a Prelude to CBT in IAPT Completed NCT02307097 Not Applicable
48 Youth Mayo Clinic Anxiety Coach Pilot Study Completed NCT02205177 Not Applicable
49 Internet-Delivered Cognitive Behavior Therapy for Anxiety and Depression Amongst French Canadians Completed NCT03043833 Not Applicable
50 Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD Completed NCT01682447 Not Applicable

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

41
Colon, Brain, Cortex, Thyroid, Pituitary, Amygdala, Breast

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 565)
# Title Authors Year
1
Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. ( 29899808 )
2018
2
The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament. ( 29649673 )
2018
3
Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. ( 29391399 )
2018
4
Bowel and Bladder Anxiety: An Obsession or a Variant of Agoraphobia? ( 29875534 )
2018
5
Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. ( 29539585 )
2018
6
Pretreatment Cardiac Vagal Tone Predicts Dropout from and Residual Symptoms after Exposure Therapy in Patients with Panic Disorder and Agoraphobia. ( 29533952 )
2018
7
Fear of Fear and Broad Dimensions of Psychopathology over the Course of Cognitive Behavioural Therapy for Panic Disorder with Agoraphobia in Japan. ( 29259145 )
2017
8
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
9
Thought Field Therapy Compared to Cognitive Behavioral Therapy and Wait-List for Agoraphobia: A Randomized, Controlled Study with a 12-Month Follow-up. ( 28676782 )
2017
10
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )
2017
11
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )
2017
12
Two Novel Cognitive Behavioral Therapy-Based Mobile Apps for Agoraphobia: Randomized Controlled Trial. ( 29175809 )
2017
13
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )
2017
14
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. ( 28845177 )
2017
15
Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )
2017
16
Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. ( 29085773 )
2017
17
Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )
2017
18
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
19
PanelA Report, IPA Congress Buenos Aires 2017: Claustro-agoraphobia, Bertram Lewin, and the oral triad 6 April 2017. ( 29148571 )
2017
20
The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. ( 27449053 )
2016
21
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report. ( 27828703 )
2016
22
Facing the fear - clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. ( 26837851 )
2016
23
Agoraphobia Related to Unassertiveness in Panic Disorder. ( 26915016 )
2016
24
A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. ( 27594602 )
2016
25
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. ( 27071857 )
2016
26
Cognitive Models for Panic Disorder With Agoraphobia: A Study of Disaggregated Within-Person Effects. ( 27123977 )
2016
27
Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. ( 26588081 )
2016
28
A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. ( 27423353 )
2016
29
Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. ( 26877119 )
2016
30
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. ( 27730622 )
2016
31
Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia. ( 27725796 )
2016
32
Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). ( 27450798 )
2016
33
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( 26663632 )
2016
34
Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. ( 27061246 )
2016
35
Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. ( 27385412 )
2016
36
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )
2016
37
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 27235836 )
2016
38
Association of human microRNAs miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. ( 26361067 )
2015
39
Evidence for chronic low-grade systemic inflammation in individuals with agoraphobia from a population-based prospective study. ( 25875094 )
2015
40
Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. ( 25722042 )
2015
41
A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. ( 26443228 )
2015
42
An admixture analysis of age of onset in agoraphobia. ( 25898330 )
2015
43
Intensive behavioral therapy for agoraphobia. ( 25479049 )
2015
44
The combined use of virtual reality exposure in the treatment of agoraphobia. ( 26150057 )
2015
45
Panic disorder and agoraphobia: A direct comparison of their multivariate comorbidity patterns. ( 26480214 )
2015
46
Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach. ( 26308791 )
2015
47
Frontal cortex absolute beta power measurement in Panic Disorder with Agoraphobia patients. ( 26093831 )
2015
48
Agoraphobia and Melancholia: Thoughts on Milrod's "Emptiness in Agoraphobia Patients". ( 26263925 )
2015
49
CLINICAL CONSEQUENCES OF THE REVISED DSM-5 DEFINITION OF AGORAPHOBIA IN TREATMENT-SEEKING ANXIOUS YOUTH. ( 25845579 )
2015
50
Social Anxiety Disorder and Agoraphobia in Dermatology Patients; Two Cases and a Review of the Literature. ( 25721467 )
2015

Variations for Agoraphobia

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Pathways for Agoraphobia

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.86 CCKBR GRPR HTR1A OPRK1 PTK7 RGS2
2 membrane GO:0016020 9.85 CCKBR GRPR HTR1A MAOA OPRK1 PTK7
3 integral component of plasma membrane GO:0005887 9.43 GRPR HTR1A OPRK1 PTK7 SLC6A2 SLC6A4
4 neuron projection GO:0043005 9.02 OPRK1 RGS2 SLC6A2 SLC6A4 STMN1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 CCKBR GRPR HTR1A OPRK1 PTK7 STMN1
2 chemical synaptic transmission GO:0007268 9.61 HTR1A OPRK1 SLC6A2
3 social behavior GO:0035176 9.46 GRPR SLC6A4
4 neurotransmitter transport GO:0006836 9.4 SLC6A2 SLC6A4
5 vasoconstriction GO:0042310 9.32 HTR1A SLC6A4
6 monoamine transport GO:0015844 9.26 SLC6A2 SLC6A4
7 behavior GO:0007610 9.16 HTR1A OPRK1
8 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.13 CCKBR GRPR OPRK1
9 dopamine uptake involved in synaptic transmission GO:0051583 8.62 SLC6A2 SLC6A4

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.32 RGS2 SLC6A2
2 neuropeptide binding GO:0042923 9.26 GRPR OPRK1
3 neurotransmitter:sodium symporter activity GO:0005328 9.16 SLC6A2 SLC6A4
4 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A2 SLC6A4
5 dopamine:sodium symporter activity GO:0005330 8.62 SLC6A2 SLC6A4

Sources for Agoraphobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....